Current stock page

Financial Data

NVO Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareDrug Manufacturers - GeneralScore data as of Sep 1, 2026

NVO

Financial Data
Novo Nordisk A/S
Healthcare· Drug Manufacturers - General
AIQ Score
NeutralAIQ Edge 9/10
Relative Leader / Watch
Strong Relative Position
Score data as of Sep 1, 2026
Last price
$45.12
-$0.21 (-0.46%)
Latest market quote
Momentum36
Value59
Quality91
Risk Resilience45
Sentiment79
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 2, 2026.

Income statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$78.49B$96.82B$78.43B$74.98B$76.86B$78.09B$85.68B$71.31B
Gross Profit$61.39B$83.23B$63.42B$57.07B$64.01B$65.2B$72.66B$60B
Operating Income
Net Income$20.99B$48.56B$26.65B$20.01B$26.5B$29.03B$28.23B$27.3B
EPS$4.74$10.93$6.06$4.5$5.96$6.54$6.34$6.13
Cash flow statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating Cash Flow$55.2B$24.08B$7.62B$46.11B$40.79B$24.59B$12.3B$43.85B
Capital Expenditure-$12.8B-$12.04B-$18.43B-$13.63B-$16.28B-$14.59B-$16.56B-$12.12B
Free Cash Flow$42.4B$12.05B-$10.81B$32.48B$24.51B$10.01B-$4.26B$31.73B
Net Cash Provided By Operating Activities$55.2B$24.08B$7.62B$46.11B$40.79B$24.59B$12.3B$43.85B
Balance sheet
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Assets$594.94B$559.22B$542.9B$512.29B$482.15B$489.16B$465.8B$397.44B
Total Debt$140.13B$146.38B$130.96B$101.21B$99.27B$118.72B$102.79B$56.97B
Cash And Cash Equivalents
Total Liabilities$373.66B$356.16B$348.86B$342.39B$314.09B$350.62B$322.31B$276.92B
Total Stockholders Equity$221.28B$203.07B$194.05B$169.9B$168.07B$138.54B$143.49B$120.52B
Key financial metrics
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio16.595.2813.4419.1518.4417.9624.6232.08
P/B ratio6.35.057.459.0211.6315.0519.3829.07
P/S ratio17.7510.5918.2620.4425.4326.7132.4549.12
Debt To Equity0.630.720.670.60.590.860.720.47
Free Cash Flow Yield
Financial ratios
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio
P/B ratio6.35.057.459.0211.6315.0519.3829.07
P/S ratio17.7510.5918.2620.4425.4326.7132.4549.12
Return On Equity9.49%23.91%13.86%11.78%15.77%20.96%19.67%22.65%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
11.72
multipleSep 1, 2026
Pb
6.15
multipleSep 1, 2026
Revenue Growth Yoy
-18.94
percentSep 1, 2026
EPS Growth Yoy
-56.63
percentSep 1, 2026
Gross Margin
80.65
percentSep 1, 2026
Operating Margin
43.13
percentSep 1, 2026
ROE
59.09
percentSep 1, 2026
ROIC
29.73
percentSep 1, 2026
Debt To Equity
0.63
ratioSep 1, 2026
FCF Yield
3.58
percentSep 1, 2026
Technical indicators
Close
45.12
priceSep 1, 2026
Volume
9,355,998
volumeSep 1, 2026
Rsi14
43.76
indexSep 1, 2026
MACD
-0.49
indexSep 1, 2026
MACD Signal
-0.39
indexSep 1, 2026
MACD Histogram
-0.1
indexSep 1, 2026
Adx14
13.26
indexSep 1, 2026
Sma50
47.92
priceSep 1, 2026
Sma200
46.37
priceSep 1, 2026
Atr14
1.32
priceSep 1, 2026
Historical Volatility
0.3
percentSep 1, 2026
Volume Ma20
11,774,102.85
volumeSep 1, 2026
Risk measures
Resilience Score
45
score_0_100Sep 1, 2026
Beta
0.35
ratioSep 1, 2026
Volatility Annual
45.82
percentSep 1, 2026
Max Drawdown
-44.84
percentSep 1, 2026
Sharpe Ratio
-0.34
ratioSep 1, 2026
Var95
-3.05
percentSep 1, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

NVO Financial Data FAQ

What is Novo Nordisk A/S's revenue?

Novo Nordisk A/S's revenue is one of the core financial data points for NVO. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Novo Nordisk A/S's revenue growing?

Revenue growth shows whether Novo Nordisk A/S is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is NVO's EPS?

NVO's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Novo Nordisk A/S's net income?

Novo Nordisk A/S's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Novo Nordisk A/S generate?

Free cash flow shows how much cash Novo Nordisk A/S generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Novo Nordisk A/S have?

Cash and debt help frame NVO's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.